Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon 5 and 2 bp deletion in exon 5.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-ADAM17, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ADAM17 also known as TACE (tumor necrosis factor-alpha converting enzyme) is a metalloprotease belonging to the ADAM (a disintegrin and metalloprotease) family. This protein functions by cleaving and shedding extracellular portions of cell surface proteins. It weighs approximately 93 kDa. ADAM17 is expressed in a range of tissues including the heart liver kidney and brain. The protein plays a role in the regulation of various biological processes through the activation and inactivation of membrane-bound precursor proteins.
Biological function summary
The ADAM17 protein regulates a multitude of cellular responses such as inflammation and growth factor signaling. It is not part of a complex but interacts with various substrates in the cell membrane. ADAM17 cleaves precursors to release soluble cytokines and growth factors like tumor necrosis factor-alpha (TNF-alpha) and epidermal growth factor receptor (EGFR) ligands which modulate cell proliferation migration and apoptosis.
Pathways
ADAM17 plays an integral role in both the TNF and EGFR signaling pathways. These pathways are important in maintaining normal cellular homeostasis. ADAM17 interacts with proteins like TNF receptors and ligands of the EGFR family integrating signaling that affects immune response and cell growth. The regulatory function of ADAM17 in these pathways makes it an important target for modulating cellular responses triggered by external stimuli.
ADAM17 has significant implications in conditions such as rheumatoid arthritis and cancer. In rheumatoid arthritis the protein's shedding activity influences inflammatory cytokines contributing to the disease’s pathogenesis alongside proteins like TNF-alpha. In cancer ADAM17's ability to release EGFR ligands affects tumor cell proliferation and metastasis with interactions involving EGFR proteins. It is a target of therapeutic interest with research focused on developing inhibitors to manage these diseases effectively.
